Navigation Links
Groundbreaking Approach to Predicting Cancer Patients' Response to Treatment Featured in Science Magazine
Date:10/27/2011

BOSTON and CAMBRIDGE, Mass., Oct. 27, 2011 /PRNewswire/ -- A potentially groundbreaking approach to predicting cancer patient response to certain treatments is described today in the electronic version of Science Magazine.  The paper describing the technology, called BH3 profiling, is published by Dr. Anthony Letai and colleagues at Boston's Dana Farber Cancer Institute. The technology assesses the ability of a key part of the cancer cell to respond to chemotherapies. This understanding provides a powerful tool for physicians to gauge ahead of time if a particular cancer treatment will, or will not work in a given patient and can be used to guide the use of existing drugs.

Letai explained, "Our experiments with BH3 profiling demonstrate that understanding of the pretreatment tumor mitochondria can offer valuable predictive information about clinical response.  As such, BH3 profiling has the potential to personalize therapy for cancer patients by predicting the quality of a patient's response to a given treatment."

This capability is in line with an FDA draft guidance document issued in July of this year calling for companion diagnostic tests for targeted therapies.

The job of commercializing this assay has been assumed by Cambridge, MA based Eutropics Pharmaceuticals, where Dr. Letai serves as chair of the SAB. Eutropics has exclusively licensed the technology from Dana Farber. Currently the test is being developed by the company for use in guiding treatments for multiple myeloma and acute myelogenous leukemia patients.

"Eutropics is uniquely positioned to provide this important test that will help cancer patients receive the appropriate treatments," said Dr. Michael Cardone, CEO of Eutropics Pharmaceuticals.  Eutropics' effort to commercialize the BH3 profiling assay is being done in collaboration with Dana Farber Cancer Institute, University of Massachusetts Medical School, M.D. Anderson Cancer Center, and the National Cancer Institute.

About the company:

Eutropics Pharmaceuticals was founded on research and technology that will enable delivery of personalized medicines to patients suffering from cancer. They seek to displace current treatment paradigms by developing novel therapies tailored to an individual's cancer profile identified by the proprietary BH3 profiling diagnostic technology.  This personalized approach utilizing unique diagnostics and therapeutics should result in more effective treatments and reduce unnecessary suffering.  The company is supported by private investors, grants from the NCI, and a loan from the Massachusetts Life Sciences Center.


'/>"/>
SOURCE Eutropics Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
2. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
3. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
4. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
5. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
6. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
7. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
8. Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research
9. Groundbreaking Ceremony in Port-au-Prince, Haiti for FilterPure Water Filtration Factory
10. Sensitechs Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility
11. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... Nevro Corp. (NYSE: NVRO), a global medical device ... of chronic pain, today reported financial results for the three ... 2016 Accomplishment & Highlights: Achieved revenue ... of 228% as reported, over the prior year ... 612% over the prior year International revenue ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The International Association ... annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected from ... be showcased and the winner revealed at the 31st annual iaedp Symposium, March 22 ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over ... on February 12th. Ms. Esparza qualified into this prestigious status after winning ... in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the ...
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s also ... We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest think ... American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why Some ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael ... “Mama June: From Not to Hot,” which will begin airing on February 24, 2017. ... to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The ...
Breaking Medicine News(10 mins):